SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair, Chief Business Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6, 2018 at 12:05 p.m. Eastern Time.
In addition to presenting a corporate overview, Mr. Fair will provide details on the Company’s portfolio programs, including the IVR drug delivery platform licensed from Juniper Pharmaceuticals, the development of vaginal tamoxifen for the treatment of VVA in ER/PR+ breast cancer patients and survivors, as well as an update on the recent positive Type C meeting with the FDA regarding the Topical 5% Sildenafil Citrate Cream, a potential treatment for female sexual arousal disorder (FSAD).
The presentation will be webcast live and may be accessed by visiting Daré’s website at http://ir.darebioscience.com. A replay of the webcast will be available for 30 business days.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive and sexual health. The company’s mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes two potential first-in-class candidates currently in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive vaginal ring, and Topical 5% Sildenafil Citrate Cream, a potential treatment for female sexual arousal disorder utilizing the same active ingredient as Viagra®. To learn more about Daré’s full portfolio of women’s health products, and mission to deliver novel therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré uses these channels to communicate with its investors and the public about the company and other issues. The information Daré posts on its investor relations website may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:
Ami Bavishi
Burns McClellan
abavishi@burnsmc.com
212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.:
Amanda Guisbond
Canale Communications
amanda@canalecomm.com
781-405-8775
Source: Daré Bioscience